Supernus Pharmaceuticals Inc (SUPN) concluded trading on Thursday at a closing price of $30.76, with 0.48 million shares of worth about $14.65 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -8.23% during that period and on April 17, 2025 the price saw a gain of about 0.16%. Currently the company’s common shares owned by public are about 55.74M shares, out of which, 53.34M shares are available for trading.
Stock saw a price change of -1.00% in past 5 days and over the past one month there was a price change of -3.97%. Year-to-date (YTD), SUPN shares are showing a performance of -14.93% which increased to 4.52% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $25.53 but also hit the highest price of $40.28 during that period. The average intraday trading volume for Supernus Pharmaceuticals Inc shares is 614.53K. The stock is currently trading -3.78% below its 20-day simple moving average (SMA20), while that difference is down -7.33% for SMA50 and it goes to -9.02% lower than SMA200.
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) currently have 55.74M outstanding shares and institutions hold larger chunk of about 108.80% of that.
The stock has a current market capitalization of $1.72B and its 3Y-monthly beta is at 0.75. PE ratio of stock for trailing 12 months is 23.33, while it has posted earnings per share of $1.32 in the same period. Its PEG reads 35.35 and has Quick Ratio of 2.16 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SUPN, volatility over the week remained 3.33% while standing at 4.22% over the month.
Stock’s fiscal year EPS is expected to drop by -37.53% while it is estimated to increase by 29.37% in next year. EPS is likely to grow at an annualized rate of 0.66% for next 5-years, compared to annual growth of -8.87% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Cantor Fitzgerald on February 19, 2025 offering a Neutral rating for the stock and assigned a target price range of between $57 and $36 to it. Coverage by Cantor Fitzgerald stated Supernus Pharmaceuticals Inc (SUPN) stock as an Overweight in their note to investors on January 06, 2025, suggesting a price target of $57 for the stock. On September 11, 2024, Piper Sandler Downgrade their recommendations, while on January 03, 2023, Jefferies Resumed their ratings for the stock with a price target of $45. Stock get a Buy rating from Jefferies on December 01, 2021.
